PRECLINICAL EVAL. OF TUBULIN BINDING AGENTS AND DUAL SPEC. PHOSP INHIB. IN RODENT

临床前评估。

基本信息

项目摘要

This Program Project Grant application is directed at identifying small molecules that inhibit dual specificity phosphatases, such as Cdc25B; tubulin/microtubules; or motor proteins. JR oxime, an analogue of Curacin A directed at the colchicine binding site of tubulin was evaluated and found to be inactive. DA-3003-1, an irreversible phosphatase inhibitor was also evaluated and found to have marginal efficacy and a short halflife. JUN-1111, a dechlorinated analogue of DA-3003-1, is currently being investigated as is another phosphatase inhibitor, 5169131. Molecules such as dictyostatin 1, related to discodermolide, and directed against the paclitaxel binding site on tubulin, have been synthesized by Dr. Curran's group and should be available for in vivo testing within the first year. This Core is responsible for the preclinical evaluation of three, targeted, small molecules each year in rodents. Determination of the maximum tolerated doses of the compounds and efficacy in early xenograft models of prostate, colon, ovarian, and/or breast cancer will be determined first. If the compounds demonstrate activity or if they are the lead compound of a series of analogues of a particular structure, this evaluation will also include development of analytical methods for detection of the compounds in biological matrices and definition of plasma pharmacokinetics after i.v. and other routes of administration of the compounds at their maximum tolerated dose. The effects of the compounds on their molecular targets within the tumor xenografts will also be investigated in additional cohorts of animals included on the pharmacokinetic studies and the efficacy studies. The compounds selected for study in this Core will have been prioritized through the decision network of the Program Project Grant. The results of the studies conducted in this Core will provide information on the metabolism and pharmacokinetics of lead compounds that will be used by the Projects and the bioformatics Core in the modification of structures or the selection of new lead compounds. Data generated in this Core will provide the basis for the support of an IND to the FDA for the most promising lead compounds.
该计划项目拨款申请旨在识别抑制双重特异性磷酸酶的小分子,如CDC25B;微管/微管;或马达蛋白。针对微管蛋白秋水仙碱结合部位的库拉星A类似物JR肟e进行了评估,发现其没有活性。不可逆磷酸酶抑制剂DA-3003-1也进行了评估,发现其疗效不明显,半衰期较短。JUN-1111是DA-3003-1的脱氯类似物,目前正在研究中,另一种磷酸酶抑制剂5169131也在研究中。Curran博士的团队已经合成了与Discodermolide相关的、针对微管蛋白上紫杉醇结合部位的dictyostatin 1等分子,并应在第一年内可用于体内测试。该中心负责每年对啮齿动物体内的三个靶向小分子进行临床前评估。最大耐受量的测定 将首先确定前列腺癌、结肠癌、卵巢癌和/或乳腺癌早期异种移植模型中的化合物和疗效。如果化合物显示出活性,或者如果它们是一系列特定结构类似物的先导化合物,这项评估还将包括开发分析方法以检测生物基质中的化合物,并定义静脉注射后的血浆药代动力学。以及以其最大耐受量给药的其他途径。这些化合物对肿瘤移植瘤内分子靶点的影响也将在包括药代动力学研究和疗效研究在内的其他动物队列中进行研究。选定的化合物 将通过计划项目赠款的决策网络确定在这一核心进行研究的优先顺序。在该核心进行的研究结果将提供有关先导化合物的新陈代谢和药代动力学的信息,这些先导化合物将被项目和生物信息学核心用于修改结构或选择新的先导化合物。在这个核心中产生的数据将为IND向FDA提供最有希望的先导化合物的支持提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JULIE L. EISEMAN其他文献

JULIE L. EISEMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JULIE L. EISEMAN', 18)}}的其他基金

Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th
抗肿瘤等药物的临床前药代动力学和药理学研究
  • 批准号:
    8655018
  • 财政年份:
    2011
  • 资助金额:
    $ 14.35万
  • 项目类别:
Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th
抗肿瘤等药物的临床前药代动力学和药理学研究
  • 批准号:
    8342342
  • 财政年份:
    2011
  • 资助金额:
    $ 14.35万
  • 项目类别:
Pharmacokinetic and Pharmacological Studies of Antitumor and other Therapeutic Agents
抗肿瘤和其他治疗药物的药代动力学和药理学研究
  • 批准号:
    8844897
  • 财政年份:
    2011
  • 资助金额:
    $ 14.35万
  • 项目类别:
Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th
抗肿瘤等药物的临床前药代动力学和药理学研究
  • 批准号:
    8429102
  • 财政年份:
    2011
  • 资助金额:
    $ 14.35万
  • 项目类别:
Pharmacokinetic and Pharmacological Studies of Antitumor and other Therapeutic Agents
抗肿瘤和其他治疗药物的药代动力学和药理学研究
  • 批准号:
    9035201
  • 财政年份:
    2011
  • 资助金额:
    $ 14.35万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296956
  • 财政年份:
    1987
  • 资助金额:
    $ 14.35万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296953
  • 财政年份:
    1987
  • 资助金额:
    $ 14.35万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296952
  • 财政年份:
    1987
  • 资助金额:
    $ 14.35万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296951
  • 财政年份:
    1987
  • 资助金额:
    $ 14.35万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296955
  • 财政年份:
    1987
  • 资助金额:
    $ 14.35万
  • 项目类别:

相似海外基金

The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
  • 批准号:
    21K17258
  • 财政年份:
    2021
  • 资助金额:
    $ 14.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
  • 批准号:
    499958-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 14.35万
  • 项目类别:
    Engage Grants Program
Uhrf1 and the DNA damage response
Uhrf1 和 DNA 损伤反应
  • 批准号:
    311915
  • 财政年份:
    2013
  • 资助金额:
    $ 14.35万
  • 项目类别:
    Studentship Programs
Improvement of RNAi efficacy by blocking RNAi inhibitors
通过阻断 RNAi 抑制剂提高 RNAi 功效
  • 批准号:
    7109912
  • 财政年份:
    2006
  • 资助金额:
    $ 14.35万
  • 项目类别:
Development of an ICMT Supported Membrane Sensor
ICMT 支持的薄膜传感器的开发
  • 批准号:
    7037706
  • 财政年份:
    2006
  • 资助金额:
    $ 14.35万
  • 项目类别:
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy
开发 CEES 诱导的皮肤毒性模型并评估水飞蓟宾功效
  • 批准号:
    7235521
  • 财政年份:
    2006
  • 资助金额:
    $ 14.35万
  • 项目类别:
PhaseI/II Clinical Trial of hHB22.7 anti-CD22 Monoclonal Antibody for Lymphoma
hHB22.7抗CD22单克隆抗体治疗淋巴瘤I/II期临床试验
  • 批准号:
    7158852
  • 财政年份:
    2006
  • 资助金额:
    $ 14.35万
  • 项目类别:
Mechanism of Formation of Polysulfane Anticancer Agents
聚硫烷抗癌剂的形成机理
  • 批准号:
    7059750
  • 财政年份:
    2006
  • 资助金额:
    $ 14.35万
  • 项目类别:
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
新型底物竞争性 Bcr-Abl 抑制剂对格列卫耐药 CM 具有活性
  • 批准号:
    7046281
  • 财政年份:
    2006
  • 资助金额:
    $ 14.35万
  • 项目类别:
Islolated Hepatic Perfusion with Oxaliplatin
奥沙利铂离体肝灌注
  • 批准号:
    7056312
  • 财政年份:
    2006
  • 资助金额:
    $ 14.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了